Business Context and Reporting Period
This Form 8-K filing by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports corporate governance events occurring on October 28, 2022. The company is a Delaware corporation listed on The Nasdaq Stock Market LLC and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on board appointments and bylaw amendments.
Material Changes
- Board Appointment: The Board appointed Bette Jacobs, Ph.D., as an Independent Director, effective October 28, 2022. She fills the seat vacated by William Adkins.
- Committee Assignments: Dr. Jacobs was appointed to the Audit Committee and the Nominating and Corporate Governance Committee.
- Bylaw Amendment: The Board adopted Second Amended and Restated Bylaws to reduce the term of service for directors from three years to one year.
Compensation and Governance Details
Dr. Jacobs' compensation package includes:
- Cash Retainer: $25,000 per annum, paid in quarterly installments.
- Equity Grant: Restricted Stock Units (RSUs) valued at $100,000 based on the closing stock price on the grant date.
- Vesting Schedule: One-third vests on the execution date, with the remaining two-thirds vesting in equal installments on the first and second anniversaries of her appointment.
The filing states there are no family relationships between Dr. Jacobs and the Company, and no related party transactions have occurred within the past three years.
Investor Verification Checklist
- Verify the impact of the reduced director term (one year) on future board election cycles.
- Confirm the specific vesting dates for Dr. Jacobs' RSUs based on the October 28, 2022 grant date.
- Review the full text of the Second Amended and Restated Bylaws (Exhibit 3.1) for additional governance changes.
- Check subsequent filings for any financial updates, as this 8-K contains no financial performance data.